Cleared Traditional

Tandem Mobi insulin pump with interoperable technology

K240309 · Tandem Diabetes Care, Inc. · Chemistry

Mar 2024

Decision

48d

Days

Class 2

Risk

About This 510(k) Submission

K240309 is an FDA 510(k) clearance for the Tandem Mobi insulin pump with interoperable technology, a Alternate Controller Enabled Insulin Infusion Pump (Class II — Special Controls, product code QFG), submitted by Tandem Diabetes Care, Inc. (San Diego, US). The FDA issued a Cleared decision on March 21, 2024, 48 days after receiving the submission on February 2, 2024. This device falls under the Chemistry review panel. Regulated under 21 CFR 880.5730.

Submission Details

510(k) Number	K240309 FDA.gov
FDA Decision	Cleared SESE
Date Received	February 02, 2024
Decision Date	March 21, 2024
Days to Decision	48 days
Submission Type	Traditional
Review Panel	Chemistry (CH)
Summary	Summary PDF

Device Classification

Product Code	QFG — Alternate Controller Enabled Insulin Infusion Pump
Device Class	Class II — Special Controls
CFR Regulation	21 CFR 880.5730
Definition	An Alternate Controller Enabled Insulin Infusion Pump (ace Insulin Pump) Is A Device Intended For The Infusion Of Insulin Into A Patient. The Ace Insulin Pump May Include Basal And Bolus Drug Delivery At Set Or Variable Rates. Ace Insulin Pumps Are Designed To Reliably And Securely Communicate With External Devices, Such As Automated Insulin Dosing Systems, To Allow Insulin Delivery Commands To Be Received, Executed, And Confirmed. Ace Insulin Pumps Are Intended To Be Used Both Alone And In Conjunction With Digitally Connected Medical Devices For The Purpose Of Insulin Delivery.